Cellectis (CLLS) Competitors $1.65 +0.10 (+6.45%) Closing price 03:59 PM EasternExtended Trading$1.56 -0.09 (-5.45%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS vs. IVA, ATXS, GOSS, AURA, AARD, OLMA, AVTE, OCGN, GLUE, and AVIRShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Inventiva (IVA), Astria Therapeutics (ATXS), Gossamer Bio (GOSS), Aura Biosciences (AURA), Aardvark Therapeutics (AARD), Olema Pharmaceuticals (OLMA), Aerovate Therapeutics (AVTE), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Its Competitors Inventiva Astria Therapeutics Gossamer Bio Aura Biosciences Aardvark Therapeutics Olema Pharmaceuticals Aerovate Therapeutics Ocugen Monte Rosa Therapeutics Atea Pharmaceuticals Cellectis (NASDAQ:CLLS) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations. Do insiders & institutionals believe in CLLS or IVA? 63.9% of Cellectis shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings & valuation, CLLS or IVA? Cellectis has higher revenue and earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectis$49.22M1.86-$36.76M-$0.86-1.92Inventiva$9.95M28.65-$199.34MN/AN/A Does the media refer more to CLLS or IVA? In the previous week, Cellectis had 3 more articles in the media than Inventiva. MarketBeat recorded 4 mentions for Cellectis and 1 mentions for Inventiva. Inventiva's average media sentiment score of 1.87 beat Cellectis' score of 0.47 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is CLLS or IVA more profitable? Inventiva has a net margin of 0.00% compared to Cellectis' net margin of -114.82%. Inventiva's return on equity of 0.00% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets Cellectis-114.82% -62.55% -21.19% Inventiva N/A N/A N/A Do analysts recommend CLLS or IVA? Cellectis presently has a consensus price target of $4.00, indicating a potential upside of 142.42%. Inventiva has a consensus price target of $10.40, indicating a potential upside of 248.99%. Given Inventiva's higher possible upside, analysts plainly believe Inventiva is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more risk & volatility, CLLS or IVA? Cellectis has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. SummaryInventiva beats Cellectis on 8 of the 14 factors compared between the two stocks. Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.15M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-1.9221.1726.1419.88Price / Sales1.86278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book0.707.518.055.38Net Income-$36.76M-$55.05M$3.15B$248.50M7 Day Performance10.00%2.45%1.85%2.97%1 Month Performance10.74%7.33%4.81%6.02%1 Year Performance-12.23%5.38%34.86%20.39% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis3.024 of 5 stars$1.65+6.5%$4.00+142.4%-19.9%$86.15M$49.22M-1.92290News CoverageGap DownIVAInventiva3.4752 of 5 stars$3.34+1.5%$10.40+211.5%-2.0%$319.41M$9.95M0.00100Positive NewsGap UpATXSAstria Therapeutics1.8294 of 5 stars$5.61-4.3%$30.00+434.8%-41.3%$316.57MN/A-3.0030GOSSGossamer Bio3.6834 of 5 stars$1.37-4.9%$7.75+465.7%+31.9%$311.40M$114.70M-5.96180AURAAura Biosciences2.3643 of 5 stars$6.15+1.8%$22.00+257.7%-15.1%$309.16MN/A-3.2450AARDAardvark TherapeuticsN/A$13.33+19.8%$31.25+134.4%N/A$289.26MN/A0.0018News CoverageAnalyst ForecastAnalyst RevisionGap DownOLMAOlema Pharmaceuticals2.6734 of 5 stars$4.19+1.5%$24.50+484.7%-60.8%$286.68MN/A-2.0870News CoveragePositive NewsAVTEAerovate TherapeuticsN/A$9.89+5.1%N/A-83.2%$286.66MN/A-3.3120Gap DownHigh Trading VolumeOCGNOcugen1.3291 of 5 stars$0.98-7.4%$6.00+511.6%-43.1%$286.51M$4.52M-5.1680High Trading VolumeGLUEMonte Rosa Therapeutics1.8015 of 5 stars$4.64+0.2%$15.50+234.1%+17.0%$285.41M$75.62M58.0190Positive NewsAVIRAtea Pharmaceuticals3.1131 of 5 stars$3.32+2.2%$6.00+80.7%+6.8%$284.13MN/A-2.0170News Coverage Related Companies and Tools Related Companies IVA Alternatives ATXS Alternatives GOSS Alternatives AURA Alternatives AARD Alternatives OLMA Alternatives AVTE Alternatives OCGN Alternatives GLUE Alternatives AVIR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLLS) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
